i
Take the 2-minute quiz
Tell us about the injury, your history, and what you've tried. No pressure, no commitment.
~2 minLongevity, built around you.Licensed US clinicians·Third-party tested·Every molecule explained
The recovery stack everyone's asking about
The two recovery peptides people stack together. Here’s the honest status.
BPC-157 and TB-500, the pair the internet calls “Wolverine,” are under FDA compounding review right now. We won't pretend they're for sale. We'll tell you exactly where they stand and get you to the front of the line the moment they're legitimately available.
Third-Party Batch TestedUS-Licensed CliniciansLive FDA Tracker
Join the people already on the Wolverine status list, the honest way.
Why sourcing is the whole game
The molecule is easy to find. The safe version isn’t.
Most peptides online ship under a “research use only: not for human consumption” label. That one phrase lets a seller skip FDA oversight, sterility testing, and any real manufacturing standard, and hands the entire risk to you.
What you’re not getting here
- No research-chemical vials.
- No “not for human use” labels.
- No anonymous overseas seller.
- A clinician, a licensed pharmacy, and a test result you can actually see.
The Peptós.LIFE lane
Prescribed by a US-licensed clinician. Compounded in a US-licensed 503A/503B pharmacy to USP sterility and potency standards. Third-party tested every batch: identity, potency, and sterility. Monitored as an actual clinical relationship, not a one-time sale.
Compounded medications are not FDA-approved. Where that applies, we say so. Status and timelines are tracked openly on our FDA Tracker.
See exactly where every compound standsIs this you?
You're here because you want it done right, not done sketchy.
You've got a nagging injury that just won't close out, and you're tired of “just rest.”
You've heard about BPC-157 and TB-500 from a podcast or a training partner.
You want them, but from someone who won't sell you a sketchy research vial.
You'd rather hear the honest version of the evidence than a hype reel.
How it works
Async by design. A clinician, not a checkout.
ii
A US-licensed clinician reviews
A real, named clinician of record reads your case and decides whether it's appropriate for you, not an anonymous approver.
~24 hrsiii
Join the status list
It isn't available to prescribe yet, and we won't pretend otherwise. Join the list and we'll tell you the moment it's legitimately available.
WaitlistWhere the stack actually stands
The honest status of the Wolverine stack, today.
Removed from Category 2 · under PCAC reviewWaitlist / coming
BPC-157 + TB-500
Both BPC-157 and TB-500 were removed from FDA Category 2 in April 2026, which is not approval, and not 503A Bulks-List eligibility, and both are on the FDA's PCAC agenda for July 23, 2026 (advisory only). Both are prohibited in competition under WADA.
Next FDA actionFDA PCAC \u00b7 July 23\u201324, 2026
See the live FDA Tracker Advisory, not authorization. A favorable vote leads to FDA rulemaking, not next-day availability, and reclassification is not the same as FDA approval.
The stack
The stack people call “Wolverine.”
A community nickname, not a clinical designation, and not something we own. Here's what the pair actually is, in plain English.
The local repair signal
BPC-157
A 15-amino-acid peptide studied for effects at the site of injury, tendon, ligament, and gut lining.
The systemic repair signal
TB-500
A thymosin β-4 fragment studied for cell migration and tissue remodeling more broadly through the body.
The community pairs them as “two layers of the same healing process”, one local, one systemic. That's a coherent narrative, not a proven synergy.
The honest evidence
What the evidence does, and does not, show.
The part most sites skip is the part that matters most. Both compounds are evidence grade D: animal-dominant, with no placebo-controlled human efficacy trials, and zero combination-trial data on the stack itself.
What the evidence shows
In animal models, BPC-157 has shown effects on angiogenesis, growth-factor signaling, and tendon and gut healing; TB-500 has shown cell-migration and anti-inflammatory effects. The two are studied for overlapping parts of repair, which is the mechanistic basis for pairing them.
What it does NOT show
There are no human randomized controlled trials of the combination, and no completed phase 2/3 trials for either peptide alone for tissue repair. The synergy story is a hypothesis, not a proven result. People report benefit the science hasn't confirmed, and pairing two grade-D peptides doesn't double the evidence, it stacks two uncertainties.
Side by side
BPC-157 and TB-500, compared honestly.
What each one does, why they're run together, and the shared regulatory status, same PCAC docket, both waitlist.
Where each stands
BPC-157: TB-500:
BPC-157The local signal · gut & soft tissue
What it does
Studied for soft-tissue and gut-lining repair support.
Best evidence
Grade D, animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials.
What we don't know
Read the BPC-157 monograph Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.
TB-500The systemic signal · soft tissue
What it does
Researched for tendon and muscle recovery support, typically paired with BPC-157.
Best evidence
Grade D, animal-dominant; the marketed fragment isn't trial-grade thymosin β4.
What we don't know
Read the TB-500 monograph Human evidence is minimal and animal-dominant; the marketed fragment differs from studied Tβ4, and antibody responses have been raised.
Why they're run together
BPC-157 works the gut-and-soft-tissue angle, proposed to support angiogenesis and tissue-repair signaling. TB-500 works the soft-tissue and cell-migration angle, a thymosin \u03b24 fragment proposed to influence actin regulation. Run together, the idea is broader coverage of a stubborn recovery problem, which is why nearly every recovery conversation names both in the same breath.
At a glance
BPC-157
TB-500
What it is
A 15-amino-acid sequence derived from a protein in gastric juice; proposed to support angiogenesis and tissue repair signaling.
A synthetic 7-amino-acid fragment related to thymosin beta-4, proposed to influence actin regulation and cell migration.
What it's for
Studied for soft-tissue and gut-lining repair support.
Researched for tendon and muscle recovery support, typically paired with BPC-157.
Evidence grade
Grade D
Grade D
Human data
Fewer than 30 humans studied; no placebo-controlled efficacy trials.
Minimal and animal-dominant; the marketed fragment differs from studied Tβ4, and antibody (immunogenicity) responses have been raised.
WADA status
Banned (S0)
Banned (S0)
Regulatory status
Key date
Peptós availability
The honest caveat
Be clear-eyed: both sit at evidence grade D, both are animal-dominant, and TB-500's marketed fragment isn't trial-grade thymosin \u03b24. Pairing two grade-D peptides doesn't double the evidence. Both are under the same FDA review, and neither is available to prescribe today.
BPC-157, status & waitlistWhere it stands, and how to get in line.TB-500, status & waitlistWhere it stands, and how to get in line.BPC-157 on the FDA TrackerIts live, dated regulatory row.TB-500 on the FDA TrackerIts live, dated regulatory row.Recovery, the peptide hubThe whole recovery line, sorted by what's real.
Provenance, not just convenience
Real clinicians. Real pharmacies. Nothing hidden.
Not a vial off the internet, a prescription, a licensed pharmacy, and a paper trail. Rendered the way premium should feel.
Prescribed by a US-licensed clinicianA real, named clinician of record reviews your plan and prescribes. No anonymous approver, no “questionnaire and done.”
Compounded in a US-licensed pharmacyHeld to USP sterility and potency standards, not a vial labeled “research use only.”
Third-party tested, every batchIndependent labs verify identity, potency, and sterility. We tell you exactly what’s in the vial.
Reviewed in ~24 hours, 100% onlineAsync by design. No waiting rooms, no mandatory video visit.
One clear monthly price. Cancel anytime.Transparent and all-in. No lock-in, no penalty.
Compounded medications aren’t FDA-approved, and we’ll always be the first to tell you which ones are.
Questions
The honest answers.
Neither peptide is available to prescribe today. Both BPC-157 and TB-500 were removed from FDA compounding Category 2 in April 2026, which is not approval and not 503A Bulks-List eligibility, and both go before the FDA's PCAC on July 23, 2026. “Removed from one list” is not the same as “legal to compound” or “available.” We track the real status on the live FDA Peptide Tracker.
Not from us. The stack is not yet available to prescribe, and we won't sell something we can't stand behind. Join the status list and you'll be first to know the moment it's legitimately available, sourced through a licensed pharmacy and batch-tested.
The Pharmacy Compounding Advisory Committee (PCAC) reviews seven peptides, including BPC-157 and TB-500, on July 23–24, 2026. It is advisory, not binding: a favorable vote leads to FDA rulemaking, not same-day pharmacy availability. We'll publish the outcome on the Tracker in plain English.
Honestly: it's early. Both compounds are evidence grade D, animal-dominant, with no placebo-controlled human efficacy trials, and there is zero combination-trial data on the stack itself. People report benefit the science hasn't confirmed. We grade it D and say so plainly, that transparency is the point.
Most peptides online ship under a “research use only: not for human consumption” label, which lets a seller skip sterility, potency, and endotoxin testing and hands the risk to you. Our path is the opposite: prescribed by a US-licensed clinician, compounded in a licensed pharmacy, and third-party batch-tested every time. That safety story is the one the gray market structurally cannot tell.
A US-licensed clinician reviews your case and decides whether it's appropriate, the clinician oversight is the point, not a footnote. Human safety data is thin; injection-site reactions are the commonly reported issue, and there are theoretical cautions (active cancer, pregnancy). Your clinician weighs all of it with you.
No. Compounded medications are not FDA-approved; they're prepared by a licensed pharmacy for an individual patient when a clinician determines they're appropriate. Today, the Wolverine stack isn't even at that stage, it's under review. Compounded, not FDA-approved, said out loud.
Get the status
Be first in line, sourced right, told the truth.
Join the status list. We'll notify you the moment the Wolverine stack is legitimately available, and keep you posted on the FDA review in plain English.
The FDA's advisory committee reviews BPC-157 and TB-500 on July 23\u201324, 2026. Join the list to get the outcome in plain English the day it lands, and your place in line if it clears. (Advisory only; not an approval or a launch date.)
No charge. No spam. Just the status, and your spot at the front of the line. By joining you agree to receive email and SMS updates; opt out anytime. Prescription compound, prescribed by a US-licensed clinician where appropriate. Not for use during pregnancy or with active cancer, your clinician decides.
Recovering from something now? NAD+ and Sermorelin are available today Compare the pair in depth: BPC-157 vs TB-500 Trusted care. Proven standards.
Physician of record48-state telehealthOutcomes published